Mode
Text Size
Log in / Sign up
N/A N=16 Double-blind Diagnostic

Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine

Sleep · Sedation Complication

Enrolled (actual)
16
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Difference in EEG Slow Wave Activity From Sham to In-phase Stimulation — 1.592; 1.694 Log(μV squared)

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
MRI (Radiation); Quantitative Sensory Testing (QST) (Diagnostic_test); Home sleep study (Diagnostic_test); Acoustic stimulation (65 decibels or db) up-slope of EEG with QST (Other); Acoustic stimulation (65db) down-slope of EEG with QST (Other); 0 db with QST (Other); Dexmedetomidine (Drug); Breathe-Squeeze Task (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Washington University School of Medicine
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference in EEG Slow Wave Activity From Sham to In-phase Stimulation
1.592; 1.694
PRIMARY
Difference in EEG Slow Wave Activity From Anti-phase to In-phase Stimulation
1.511; 1.694
PRIMARY
Difference in EEG Slow Wave Density From Anti-phase to In-phase Stimulation
6.9; 6
PRIMARY
Difference in EEG Slow Wave Density From Sham to In-phase Stimulation
6; 4.3
SECONDARY
Difference of Reactivity to Thermal Stimulation From Anti-phase to In-phase Stimulation
48.2; 50.5
SECONDARY
Difference of Reactivity to Thermal Stimulation From Sham to In-phase Stimulation
48.5; 50.5
SECONDARY
Slow Wave Activity Calculated During N3 Sleep
8830 0.57

Summary

Prospective within-subject study of dexmedetomidine sedation paired with CLAS conditions in repeated blocks. Intervention will consist of CLAS in-phase with EEG slow waves. Anti-phase stimulation will serve as an active control while sham stimulation will serve as a passive control.

Eligibility Criteria

Inclusion Criteria

  • Age 18-40 years
  • Healthy volunteers (American Society of Anesthesiologists Physical Status 1-2).

Exclusion Criteria

  • Diagnosed sleep disorders
  • Habitually short sleepers
  • Diagnosed psychiatric disorders
  • Use of psychoactive medication (e.g., antidepressants, mood stabilizers or antipsychotics), diagnosed hearing disorder
  • Neck circumference > 40 cm
  • Body Mass Index > 30
  • Acknowledged recreational drug or nicotine use
  • Resting heart rate during slow wave sleep 50 ºC).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04206059). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search